---
title: "These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286424446.md"
description: "Avalo Therapeutics reported a narrower Q1 loss of 98 cents per share, beating estimates of $1.13. Positive results from the Phase 2 LOTUS trial for abdakibart signal a transformative period for the company. Analysts maintain Buy ratings but adjust price targets: HC Wainwright lowers from $40 to $35, Mizuho raises from $39 to $45, and Wedbush lowers from $40 to $34. Avalo shares closed at $19.85."
datetime: "2026-05-14T13:18:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286424446.md)
  - [en](https://longbridge.com/en/news/286424446.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286424446.md)
---

# These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

**Avalo Therapeutics Inc** (NASDAQ:AVTX) reported a narrower-than-expected loss for the first quarter on Wednesday.

The company posted quarterly losses of 98 cents per share which beat the analyst consensus estimate of loss of $1.13 per share.

“The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent clinical response across both HiSCR75 and HiSCR50 endpoints, mark the beginning of a transformative period for Avalo,” said Garry Neil, MD, Chief Executive Officer of Avalo. “With our recently secured financing, Avalo is well-positioned to advance abdakibart into a registrational phase 3 program. Our focus remains on delivering this innovative mechanism of action via a patient-friendly potential monthly dosing regimen to provide a much-needed new treatment option for those living with HS.”

Avalo Therapeutics shares closed at $19.85 on Wednesday.

These analysts made changes to their price targets on Avalo Therapeutics following earnings announcement.

-   HC Wainwright & Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and lowered the price target from $40 to $35.
-   Mizuho analyst Joseph Catanzaro maintained the stock with an Outperform rating and raised the price target from $39 to $45.
-   Wedbush analyst Robert Driscoll maintained the stock with an Outperform rating and lowered the price target from $40 to $34.

**Considering buying AVTX stock? Here’s what analysts think:**

_Photo via Shutterstock_

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty](https://longbridge.com/en/news/286366040.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results](https://longbridge.com/en/news/286141162.md)